Journal: The Journal of pharmacology and experimental therapeutics

Article Title: Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism.

doi: 10.1124/jpet.121.000956

Figure Lengend Snippet: Fig. 5. The effect of empagliflozin on protein phosphorylation after I/R injury. Left: Western blots of p-GSK-3b and t-GSK-3b (A), p-AKT and t-AKT (B), p-ERK1/2 and t-ERK1/2 (C), p-STAT-1 and t-STAT-1 (D), p-STAT-3 and t-STAT-3 (E), p-STAT-5 and t-STAT-5 (F) in lung tissues after I/R injury. Right: bar graph showing mean ratio of the phospho-/total band densities. **P < 0.01, ***P < 0.001, versus sham-operated mice; ###P < 0.001, versus control mice. n 5 5 per group.

Article Snippet: The primary antibodies used in this study were: p-glycogen synthase kinase-3b (GSK-3b), phosphorylated GSK-3b (Ser9); t-GSK-3b, total GSK-3b; p-protein kinase B (AKT), phosphorylated AKT (ser473); t-AKT, total AKT; pERK, phosphorylated ERK 1/2 (Thr202/Tyr204); t-ERK, total ERK1/2; p-signal transducer and activator of transcription (STAT)-1, phosphorylated STAT-1 (Tyr701); t-STAT-1, total STAT-1; P-STAT-3, phosphorylated STAT-3 (Tyr705); t-STAT-3, total STAT-3; p-STAT-5, phosphorylated STAT-5 (Tyr694); t-STAT-5, total STAT-5 (all primary antibodies, 1:1000, Cell Signaling, Danvers, MA).

Techniques: Phospho-proteomics, Western Blot, Control

Journal: The Journal of pharmacology and experimental therapeutics

Article Title: Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism.

doi: 10.1124/jpet.121.000956

Figure Lengend Snippet: Fig. 5. The effect of empagliflozin on protein phosphorylation after I/R injury. Left: Western blots of p-GSK-3b and t-GSK-3b (A), p-AKT and t-AKT (B), p-ERK1/2 and t-ERK1/2 (C), p-STAT-1 and t-STAT-1 (D), p-STAT-3 and t-STAT-3 (E), p-STAT-5 and t-STAT-5 (F) in lung tissues after I/R injury. Right: bar graph showing mean ratio of the phospho-/total band densities. **P < 0.01, ***P < 0.001, versus sham-operated mice; ###P < 0.001, versus control mice. n 5 5 per group.

Article Snippet: The primary antibodies used in this study were: p-glycogen synthase kinase-3b (GSK-3b), phosphorylated GSK-3b (Ser9); t-GSK-3b, total GSK-3b; p-protein kinase B (AKT), phosphorylated AKT (ser473); t-AKT, total AKT; pERK, phosphorylated ERK 1/2 (Thr202/Tyr204); t-ERK, total ERK1/2; p-signal transducer and activator of transcription (STAT)-1, phosphorylated STAT-1 (Tyr701); t-STAT-1, total STAT-1; P-STAT-3, phosphorylated STAT-3 (Tyr705); t-STAT-3, total STAT-3; p-STAT-5, phosphorylated STAT-5 (Tyr694); t-STAT-5, total STAT-5 (all primary antibodies, 1:1000, Cell Signaling, Danvers, MA).

Techniques: Phospho-proteomics, Western Blot, Control

Journal: Oncology reports

Article Title: Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.

doi: 10.3892/or.2018.6508

Figure Lengend Snippet: Figure 6. Cells overexpressing SOCS1 reveal inhibition of the JAK2/STAT pathway. (A) U937 and THP‑1 cells transfected with the SOCS1‑GFP vector. Cells were imaged with LSM 510 (ZEISS AG, Oberkochen, Germany). (B) Proliferation curves of transfected cells. Cell viability was determined by the CCK‑8 assay. (C) The apoptosis rate of transfected cells. Flow cytometric analysis of cell apoptosis detected by Annexin V staining. This experiment was performed twice. (D) Expression of downstream pathway proteins in cells with the empty vector and after transfection of the SOCS1 gene in U937 and THP‑1 cell lines. Subclone 1 and 2 are each from SOCS1‑transfected AML cell lines. The control represents the empty vector, SOCS1+ represents cells transfected with SOCS1. *P<0.05.

Article Snippet: The membranes were probed with antibodies for SOCS1 (1:1,000; cat. no. 3950), t-JAK2 (1:1,000; cat. no. 4040), p-JAK2 (1:1,000; cat. no. 4406), t-STAT3 (1:1,000; cat. no. 9139), p-STAT3 (1:1,000; cat. no. 52075), t-STAT5 (1:1,000; cat. no. 25656), p-STAT5 (1:1,000; cat. no. 4322) and β-actin (1:2,000; cat no. 3700), and then incubated with anti-rabbit IgG, horseradish peroxidase (HRP)-linked secondary antibody (1:3,000; cat. no. 3700) (all from Cell Signaling Technology, Inc., Danvers, MA, USA) for 1 h for chemiluminescent detection.

Techniques: Inhibition, Transfection, Plasmid Preparation, CCK-8 Assay, Staining, Expressing, Control